CTOR

시간 외 거래: .99 0.02 +2.06%

Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1196)

(347) 627-0058

420 LEXINGTON AVE,, NEW YORK

최신 SEC 제출 서류

CTOR's Discussions on Twitter

CTOR을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR	0.97	74.83M	0	0	0	0.00
ZTS	176.42	79.51B	9.15B	2.43B	2.31B	4.92
TAK	13.53	42.89B	30.27B	1.93B	3.45B	0.444
HLN	9.43	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.49	18.51B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.00	15.37B	15.24B	-646.50M	1.88B	1.53

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

CTOR을(를) 다른 주식과 비교

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - Kilgore News Herald

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - BioSpace

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - BioSpace

CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India

CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa

CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com

Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com

Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex

Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News

Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's

Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex

XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World

CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada

CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow

A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News

Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com

Citius Oncology Inc. (CTOR) requires closer examination - US Post News

Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks

CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle

Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex

Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia

Citius Oncology Inc. completes strategic acquisition - Investing.com

Citius Oncology Finalizes Merger and Modifies Stock Structure - TipRanks

Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ

Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex

Citius merges oncology subsidiary with TenX Keane - Yahoo Finance

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow

Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024 - Marketscreener.com

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com

TenX Keane addresses trading halt, continues toward combination closing - TipRanks

New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online

US FDA approves Citius' therapy for rare blood cancer - Reuters.com

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목